Anti-Mouse CD90 (Thy-1) [T24/31] – Purified in vivo GOLD™ Functional Grade

Clone T24/31 is most commonly used in vivo in mice for the specific depletion of T cells, including both thymocytes and peripheral T lymphocytes. This depletion is essential in studies analyzing the role of T cells in immune responses, tissue-resident memory T cell (TRM) function, transplantation tolerance, inflammatory models, and tumor immunity.

Key In Vivo Applications of Clone T24/31 in Mice

• T Cell Depletion:
  Clone T24/31 is a monoclonal antibody targeting mouse CD90 (Thy-1), a marker broadly expressed on murine T cells. Administering this antibody in vivo leads to the efficient and reproducible depletion of T lymphocytes, which is widely utilized in immunology research.
• Studies of Tissue-Resident Memory T Cells (TRM):
  The antibody is frequently employed to study the function of TRM by depleting T cells specifically in various tissues, allowing researchers to dissect the roles these cells play in local immunity, inflammation, and infection models.
• Transplantation and Graft Rejection Models:
  By depleting T cells, T24/31 helps assess the importance of T cell-mediated responses in models of tissue and organ transplantation, including studies of graft acceptance, tolerance, or rejection.
• Autoimmunity and Inflammation:
  T24/31 is also applied in models of autoimmune disease to determine the contribution of T cells to disease onset, progression, and in evaluating candidate immune interventions.
• Tumor Immunology:
  It is used to assess the role of T cells in tumor growth or anti-tumor immunity by depleting these cells before, during, or after tumor establishment.

Technical Notes

• Specificity:
  Clone T24/31 recognizes a conserved, non-polymorphic determinant on mouse CD90 (Thy-1), binding to both the Thy1.1 and Thy1.2 allelic forms, thus it can be used in all common mouse strains.
• Other Applications:
  While primarily used in vivo for T cell depletion, T24/31 is also validated for flow cytometry, functional assays (such as proliferation or cytotoxicity), and immunohistochemistry.
• Depletion Characteristics:
  Administration of T24/31 typically results in rapid and profound reduction of circulating and tissue-resident T cells, facilitating robust experimental control of T cell-dependent processes.

Summary:
The main in vivo application of clone T24/31 in mice is selective T cell depletion for the investigation of immune mechanisms, with widespread use in studies of memory T cell biology, immunity, transplantation, autoimmunity, and tumor models.

Commonly used antibodies and proteins paired with T24/31 (anti-mouse CD90/Thy-1) in the literature include other cell surface markers and cytoskeletal proteins that enable characterization and discrimination of cell types in immunological and neurobiological assays.

Key antibodies and proteins used with T24/31:

• Beta tubulin: Frequently combined with T24/31 in immunocytochemistry (ICC) for dual labeling, allowing simultaneous visualization of neuronal or glial structures and cell surface markers.
• CD44, CD45, CD3, CD4, CD8: These markers are often co-stained to distinguish between subpopulations of lymphocytes, stem cells, or immune cells in flow cytometry and immunohistochemistry, with CD90/Thy-1 serving as a stem cell or neuronal marker.
• Other anti-mouse CD90 clones (e.g., OX-7): Sometimes compared or used alongside T24/31 for validation or cross-reactivity studies.
• Cytoskeletal proteins (e.g., actin): Used for validating cell identification and ensuring specificity, particularly when assessing neuronal lineages.
• Mass spectrometry validation: Sometimes paired with T24/31 and orthogonally validated antibodies (e.g., using mass spec or recombinant expression) to ensure result specificity.
• Western blot controls: Housekeeping proteins such as GAPDH or β-actin are often used as protein loading controls in conjunction with T24/31 detection in Western blot assays.

In immunological studies, T24/31 is most often paired with markers that distinguish T cells, stem/progenitor cells, or that enable lineage tracing, as well as with proteins like beta tubulin for dual visualization in neural tissue. The choice of antibodies depends on the experimental context—whether the aim is immunophenotyping, stem cell isolation, or neuronal cell identification.

Clone T24/31 is primarily cited in the scientific literature as a monoclonal antibody targeting CD90 (Thy-1) for in vivo and ex vivo depletion of T cells in mice, especially in studies on tissue-resident memory T cells (TRM) and immune responses. Key findings from its citations include:

• T cell depletion: Clone T24/31 is widely used to deplete T cells in mouse models, enabling researchers to study the roles of different T cell populations—particularly tissue-resident memory T cells—in immunity and inflammation.
• Study of tissue-resident memory T cells (TRM): The antibody allows for the specific removal of TRM cells, facilitating investigations into their function in various disease models or during infection.
• Functional immunology studies: Use of this clone is routinely reported in research examining mechanisms of immune regulation, such as monocyte-to-macrophage differentiation, and in models of infection or inflammation.

Additional details:

• CD90 (Thy-1) is a cell surface glycoprotein broadly used as a marker for various immune and non-immune cells, including T lymphocytes.
• The antibody is often used in mouse experiments to create loss-of-function conditions by depleting certain cell types, providing insights into their physiological and pathological roles.
• In addition to immunodepletion, at least one citation notes that clone T24/31 can promote neurite outgrowth in neuron studies, though this is a less common application.

In summary, the dominant use of clone T24/31 in the literature is as a tool for targeted T cell depletion in mouse models, which is foundational for dissecting immune mechanisms and cell-specific functions in vivo.

There is no standardized dosing regimen for clone T24/31 (an anti-mouse CD90/Thy-1 monoclonal antibody) across different mouse models; regimens are adapted based on the experimental context, including mouse strain, tumor or disease model, and the compound or effect under investigation.

Key supporting details:

• Dosing is highly variable: The regimen for T24/31 may be influenced by factors such as the type of tumor established, the test compound used, and the specifics of the mouse strain employed.
• Experimental adaptation: Researchers modify dosing according to the pathology and the aim of the experiment (e.g., depletion, functional assays, in vivo targeting).
• No universal protocol: Unlike some antibodies where fixed doses are published for specific models, T24/31 does not have a recommended universal dose; investigators must optimize conditions for each study.
• Related comparison: This flexibility in dosing mirrors other anti-CD90 antibodies (such as clone OX-7), whose regimens are likewise tailored depending on the model and study goals.

If a specific dosing regimen for T24/31 in a particular mouse model or application is required, it typically necessitates consulting individual experimental publications or contacting reagent suppliers for their protocol recommendations, as a universal standard is not available.